Fig. 4From: Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancerComparison between primary and acquired MET fusions in lung cancer patients. A, C Waterfall plots for patients harboring primary and acquired MET fusions. B, D Functional enrichment based on MET-fused genes in lung cancer patients harboring primary and acquired MET fusionsBack to article page